Haitham Tuffaha

Professor Haitham Tuffaha serves as Affiliate Professor of the School of Pharmacy and Pharmaceutical Sciences and Professorial Research Fellow at the Centre for the Business and Economics of Health (Faculty of Business, Economics and Law) at The University of Queensland. He also holds affiliations with the Centre for Innovation in Pain and Health Research. As lead of the Effective and Efficient Healthcare program and Health Technology Assessment division at CBHE, his work directly informs Australian healthcare policy through Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) evaluations.

His research focuses on economic evaluation of health interventions, value-based healthcare implementation, and cancer economics, pioneering Value of Information analysis applications to optimize clinical trial efficiency. Key research areas include:

• Health Technology Assessment methodologies
• Genetic testing and targeted therapy economics
• Medication safety and utilization
• Exercise oncology cost-effectiveness
• Resource allocation frameworks for precision medicine

Analysis of his 100+ publications reveals consistent emphasis on prostate cancer interventions, genetic testing cascade models, and implementation economics, with recent work expanding into gut-brain interaction disorders and telehealth rehabilitation. His methodological contributions center on Value of Information frameworks that bridge research investment decisions with clinical implementation.

Professor Tuffaha chairs the ISPOR-Oncology Group and serves as Associate Editor for Value in Health, with editorial roles at Medical Decision Making and PharmacoEconomics-open. His leadership extends to co-developing the Australian Clinical Trials Alliance Research Prioritisation Framework.

As chief investigator on over $45 million in Category 1 grants (NHMRC, MRFF, ARC), he directs projects for the Department of Health evaluating novel drugs and devices. His research has directly influenced allocation of nearly $1 billion in new health technologies in Australia over the past decade.

His leadership spans the Centre for Business and Economics of Health, where he directs the Effective and Efficient Healthcare program, and collaborative networks including the Safe and Effective Medication Collaborative. Current initiatives focus on optimizing medicine information handover post-discharge and value-based implementation of precision oncology.